RNA, U4atac small nuclear 14, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4ATAC14P profile across patient tissues and cancer cell-line models. RNU4ATAC14P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RNU4ATAC14P is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, RNU4ATAC14P RNA expression shows 5,666 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, THCA, and STAD as cancer lineages where RNU4ATAC14P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4ATAC14P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4ATAC14P survival associations across molecular data types. RNU4ATAC14P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4ATAC14P RNA expression–survival associations across cancer types. High RNU4ATAC14P expression shows unfavorable associations in UCEC, ACC, READ, LIHC and GBM, but favorable associations in BLCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for RNU4ATAC14P RNA expression.
This table summarizes RNU4ATAC14P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4ATAC14P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4ATAC14P shows lower tumor expression in THCA. The THCA box plot shows higher RNU4ATAC14P RNA expression in normal versus tumor tissue (log2 FC = −0.070, t-test p = .025).
This table shows molecular features associated with RNU4ATAC14P in patient tissues and cancer cell lines. In patient samples, RNU4ATAC14P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
